Periollimel N 4 weeks
L-Alanine 9.16g · L-Arginine 6.2g +23 more
Solution · Prescription medication · Combination
Baxter Korea Co., Ltd.
MFDS item code 201205400 · Approved 2012.06.05 · Insurance code 078200201,078200211,078200221,646601510
Improvement of nutritional status through intravenous provision of nutrients (fluids, electrolytes, amino acids, etc.)
This medication is used to supplement fluids, electrolytes, amino acids, and calories in pediatric patients over 2 years of age and adult patients who cannot adequately receive nutrition orally or through the gastrointestinal tract.
Determine the dose and bag size based on the patient's condition, energy expenditure, metabolic capacity, body weight, and additional calories or protein supplied orally or through the gastrointestinal tract. Trace elements, vitamins, electrolytes, etc. may be added depending on the patient's condition. Do not exceed the maximum daily dose stated below. Because the composition of the multi-chamber bag is fixed, it may not be possible to meet all of the patient's nutritional requirements at the same time. There may be clinical situations in which the patient requires amounts of nutrients different from those provided by the fixed composition of this medicine. In such cases, any dose adjustments must take into account the effects on the administration of all the other nutrient components of this medicine. Recommended daily intake - 0.16 g-0.35 g of nitrogen per kg of body weight (1 g-2 g of amino acids per kg of body weight), depending on the patient's nutritional status and degree of catabolism - 20-40 kcal of total energy per kg of body weight - 20-40 mL of total volume per kg of body weight or 1-1.5 mL per kcal expended Maximum daily dose - The maximum daily dose is 40 mL per kg of body weight (equivalent to 1.0 g of amino acids, 3.0 g of glucose, 1.2 g of fat, 0.8 mmol of sodium, and 0.6 mmol of potassium per kg of body weight) Infusion rate - Do not exceed an infusion rate of 3.2 mL/kg per hour. (Equivalent to 0.08 g/kg of amino acids, 0.24 g/kg of glucose, and 0.10 g/kg of fat per hour) 3. Method and duration of administration - Because of its low osmolarity, this medicine is infused through a central or peripheral vein. The recommended administration period is 12~24 hours. Parenteral nutrition may be continued as needed depending on the patient's condition. - In general, gradually increase the infusion rate during the first hour after starting administration, adjusting it in consideration of the total dose, daily dose, and infusion time.
Children 2 years of age and older - The daily requirements for dose, nitrogen, and calories decrease with age. - In general, start young children on a low dose and gradually increase it to the maximum dose. Patients 2 years to 11 years of age - The limiting factor for the daily dose is the magnesium concentration, and the limiting factor for the hourly rate is the fat concentration. - The maximum daily dose is 45 mL per kg of body weight (equivalent to 1.1 g of amino acids, 3.4 g of glucose, 1.4 g of fat, and 31.5 kcal of total energy per kg of body weight) - Do not exceed an infusion rate of 4.3 mL/kg per hour. (Equivalent to 0.11 g/kg of amino acids, 0.32 g/kg of glucose, and 0.13 g/kg of fat per hour) Patients 12 years to 18 years of age - The limiting factor for the daily dose is the magnesium concentration, and the limiting factor for the hourly rate is the glucose concentration. - The maximum daily dose is 45 mL per kg of body weight (equivalent to 1.1 g of amino acids, 3.4 g of glucose, 1.4 g of fat, and 31.5 kcal of total energy per kg of body weight) - Do not exceed an infusion rate of 3.2 mL/kg per hour (equivalent to 0.08 g/kg of amino acids, 0.24 g/kg of glucose, and 0.10 g/kg of fat per hour).
This medication must be used according to the doctor's instructions, and it should not be taken arbitrarily without medical advice. If symptoms of anaphylactic reactions such as fever, chills, rash, or difficulty breathing occur during administration, the use should be immediately stopped and medical personnel should be informed. This medication may form precipitates when administered with intravenous calcium-containing preparations or with the antibiotic ceftriaxone, so do not use the same infusion equipment simultaneously. Especially in premature infants and low-birth-weight infants, the lipid component of this medication may not be metabolized properly, leading to elevated free fatty acid levels in the blood, and serious issues such as fat accumulation in pulmonary vessels may arise if administered to premature infants with serious respiratory diseases. Moreover, it should not be administered to specific patient groups such as preterm infants, newborns, children under 2 years of age, patients allergic to eggs, soybeans, peanuts, corn, patients with severe renal impairment or liver disease, and patients with amino acid metabolism disorders. In patients with renal failure, diabetes, liver dysfunction, or heart failure, which obscure fat metabolism, careful administration is required, and the internal fluid and electrolyte status must be stable prior to administration. Overdose or excessive infusion rates may cause adverse reactions such as sweating, fever, chills, headache, rash, difficulty breathing, so these symptoms should lead to immediate cessation of administration. During administration, regular monitoring of fluid and electrolyte balance, blood sugar, liver and kidney function, and coagulation status should be performed to detect any abnormalities. In patients with impaired fat metabolism, this medication may induce lipid overload syndrome, which may lead to liver dysfunction, anemia, coagulation abnormalities, requiring caution. Peripheral venous administration may cause thrombophlebitis, therefore the infusion site should be inspected daily, and if extravascular leakage occurs, administration should be stopped immediately and appropriate treatment should be received. Interactions may occur when this medication is mixed with or administered simultaneously with other drugs, so care should be taken when using it with calcium-containing products, ceftriaxone, ampicillin, etc. The safety for pregnant or breastfeeding women has not been established, so this medication should only be administered when the therapeutic benefits outweigh the risks. It should not be administered to children below the age of 2, and when administered to children over 2, pediatric formulations must be used, and vitamins and trace elements must be supplemented. Blood tests within 5-6 hours after administration may be affected by the lipid component of this medication, so the timing of testing should consider this point. In cases of overdose, symptoms like acidosis, excessive circulatory blood volume, vomiting, and headache may occur, and blood dialysis may be required as needed. Finally, this medication should not be used if its packaging is damaged, or if there is an abnormality in the solution, and the condition of the solution should be checked prior to administration.
Fever, chills, rash, dyspnea, sweating, headache, skin rash (erythematous, papular, pustular, maculopapular, generalized rash), itching, flushing, tachycardia, loss of appetite, hypertriglyceridemia, abdominal pain, diarrhea, nausea, vomiting, hypertension, pain, irritation, swelling/edema, erythema/warmth, skin necrosis, vesicles/bullae, inflammation, sclerosis, skin tightness, hyperlipidemia syndrome, hepatic steatosis, hepatomegaly, splenomegaly, liver dysfunction, anemia, leukopenia, thrombocytopenia, coagulopathy, coma, thrombocytopenia, cholestasis, hepatomegaly, jaundice, hypersensitivity reaction, liver disease related to intravenous nutrition, increased alkaline phosphatase in the blood, increased transaminases, increased bilirubin in the blood, elevated liver enzymes, azotemia, pulmonary vascular embolism, pulmonary vascular deposits, extravasation, thrombophlebitis, acidosis, hypervolemia, nausea, warmth, hyperglycemia, glucosuria, hyperosmolar syndrome, symptoms of extravasation, pain due to extravasation, irritation, swelling/edema, erythema/warmth, skin necrosis, vesicles/bullae, inflammation, sclerosis, skin tightness
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to prevent air or moisture ingress. It should be stored at room temperature, taking care to avoid being too cold or freezing.
A single transparent plastic bag containing a clear liquid, separated into three compartments by two membranes, with the amino acid solution and sugar solution being clear, colorless to light yellow, and the lipid solution being homogeneously cloudy.
1000, 1500, 2000ml/bag
Even with the same ingredient, strength, dosage form and how it is taken can differ.
L-Alanine 9.16g · L-Arginine 6.2g +23 more
Solution · Prescription medication · Combination
Baxter Korea Co., Ltd.
L-Glutamic Acid 7.11g · L-Leucine 9.87g +23 more
Solution · Prescription medication · Combination
Baxter Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.